Growth Metrics

Gilead Sciences (GILD) Capital Expenditures Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -27.23%
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 51.53%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 6.72%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 14.83%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -0.53%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.44%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 2.39%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -27.39%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 7.67%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.39%
Dec 31, 2025 4.24%
Sep 30, 2025 -2.17%
Jun 30, 2025 -9.21%
Mar 31, 2025 -25.05%
Dec 31, 2024 -1.96%
Sep 30, 2024 0.48%
Jun 30, 2024 2.99%
Mar 31, 2024 -13.99%
Dec 31, 2023 5.91%
Sep 30, 2023 -7.67%
Jun 30, 2023 -0.94%
Mar 31, 2023 -13.94%
Dec 31, 2022 -3.75%
Sep 30, 2022 -7.75%
Jun 30, 2022 -8.23%
Mar 31, 2022 1.39%
Dec 31, 2021 -14.32%
Sep 30, 2021 -5.93%
Jun 30, 2021 -26.28%
Mar 31, 2021 -8.02%
Dec 31, 2020 -6.30%
Sep 30, 2020 6.31%
Jun 30, 2020 5.15%
Mar 31, 2020 13.16%
Dec 31, 2019 6.30%
Sep 30, 2019 0.34%
Jun 30, 2019 -3.21%
Mar 31, 2019 10.22%
Dec 31, 2018 14.32%
Sep 30, 2018 -16.42%
Jun 30, 2018 20.20%
Mar 31, 2018 19.57%
Dec 31, 2017 9.62%
Sep 30, 2017 -1.50%
Jun 30, 2017 10.57%
Mar 31, 2017 -10.39%
Dec 31, 2016 35.00%
Sep 30, 2016 74.63%
Jun 30, 2016 65.17%
Mar 31, 2016 65.77%
Dec 31, 2015 -14.95%
Sep 30, 2015 62.55%
Jun 30, 2015 65.99%
Mar 31, 2015 74.84%
Dec 31, 2014 85.63%
Sep 30, 2014 28.06%
Jun 30, 2014 50.61%
Mar 31, 2014 122.59%
Dec 31, 2013 43.26%
Sep 30, 2013 50.97%
Jun 30, 2013 41.29%
Mar 31, 2013 49.34%
Dec 31, 2012 115.43%
Sep 30, 2012 54.30%
Jun 30, 2012 21.45%
Mar 31, 2012 -47.90%